GlobeNewswire

Eolus signs agreement with Aquila Capital for the sale of the 400 MW Norwegian wind farm Oyfjellet

Share

Hässleholm, Sweden, July 12, 2019

Eolus has signed a share purchase agreement with Aquila Capital regarding the sale of wind farm Oyfjellet in Norway. The wind farm has a planned capacity of 400 MW. The preliminary purchase price amounts to EUR 30 million.

The transaction covers the sale of 100% of the shares of the project company that holds all the project rights for the wind power project, including a 15-year power purchase agreement with Alcoa Norway. The wind farm is located close to Mosjøen in Vefsn municipality in Norway.

The closing of the transaction, which is foreseen to take place during the autumn 2019 is subject to fulfillment of several conditions, such as granted detail plan (MTA-plan), procurement of wind turbines, grid connection agreement and balance of plant agreements.

At closing of the transaction, the parties have also agreed to sign a construction management agreement by which Eolus will manage the construction of the wind farm on behalf of Aquila. Eolus’ revenues under the construction management agreement is estimated to be approximately EUR 23 million. Eolus’s final revenues from both the share purchase agreement and the construction management agreement may deviate substantially upwards or downwards from the preliminary figures depending on the successful delivery of the wind farm. Final purchase prices will be calculated when the wind farm has been completed, which is expected to take place during the second half of 2021. The construction of the wind farm will be financed by Aquila.

Eolus has also been entrusted to provide technical, operational and administrative services during fifteen years to the wind farm to maximize outcome and production from the facility.

-The 400 MW Oyfjellet project is truly demonstrating the competitiveness of onshore wind power in the Nordics. Teaming up with an experienced investor as Aquila Capital makes it possible for us to start construction of the project as soon as the final conditions are met. The wind farm will supply Alcoa with renewable electricity for many years and provide local job opportunities both during construction and operation, says Eolus CEO Per Witalisson.

-The whole Eolus team is very proud of the trust that Aquila once again is placing in our company, both constructing and managing wind farm Oyfjellet. The site provides excellent conditions for wind power and to be part of bringing the project into operation together with Aquila is a privilege says Eolus COO Marcus Landelin.

Roman Rosslenbroich, Co-Founder and CEO of Aquila Capital, comments: “We are truly delighted to become the sponsor of Project Oyfjellet on behalf of our client and we are looking forward to continuing our good cooperation with Eolus on this Nordic landmark project. Project Oyfjellet is not only impressive by its sheer magnitude and technical characteristics, it also stands exemplary for what it will take to create a sustainable future for the generations to come: Visionary developers like Eolus, dedicated investors like us and responsibly acting industry players like Alcoa – and of course supportive governments and authorities.”

In March 2018 Wind farm Oyfjellet entered into a power purchase agreement with Alcoa Norway. During 15 years Alcoa will purchase all the electricity produced at the wind farm to provide its production plant in nearby Mosjøen with locally produced electricity.

For further information contact:

Per Witalisson, CEO, +46 10 199 88 02
Marcus Landelin, COO +46 10 199 88 16

The information in this press release is disclosed pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of head of communication Johan Hammarqvist on July 12, 2019, at 8.30 AM CET.

About Eolus:
Eolus Vind AB is one of the leading wind power developers in the Nordics. Eolus is active in the whole value chain from development of green field projects to construction and operation of wind farms. Eolus offers attractive and competitive investments in the Nordic and Baltic countries as well as the United States to both local and international investors. Founded in 1990, Eolus has constructed more than 540 wind turbines of the approximately 3 600 wind turbines operating in Sweden. Eolus has signed contracts for over 800 MW of asset management services of which 420 MW is in operation.

Eolus Vind AB has about 11 500 shareholders. Eolus shares are listed at Nasdaq Stockholm.

For more information about Eolus, please visit www.eolusvind.com

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

AMG Advanced Metallurgical Group N.V. Announces Weekly Share Repurchase Program Transaction Details19.7.2019 21:00:00 CESTPress release

Amsterdam, 19 July 2019 --- AMG Advanced Metallurgical Group N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") reports the repurchases made under its share repurchase program announced on 8 April 2019 and effective from 9 April 2019. Information regarding the progress of the share repurchase program and the aggregate of the transactions (calculated on a daily basis) for the period 15 July 2019 through 19 July 2019 can be found in the bottom half of the table below. Further detailed information regarding both the progress of the share repurchase program and the overall trades made on a daily basis can be accessed via the Investors section of the Company’s website, or clicking the following link: https://amg-nv.com/investors/share-buyback/ Share Repurchase Program Overall progress Share Repurchase Program: Total Repurchase Amount in Shares 2,915,630 Cumulative Repurchase Amount EUR 63,511,098 Cumulative Quantity Repurchased 2,534,054 Cumulative Average Repurchase Price EUR 25.06 Start Date 9 April

Ossur Hf : Össur acquires College Park Industries19.7.2019 17:00:00 CESTPress release

Reykjavik, 19 July 2019 Össur has signed an agreement to acquire College Park Industries, a global provider of lower and upper limb prostheses and supporting services. College Park has over 140 employees and is headquartered in Detroit, USA. Total sales amounted to USD 22 million in 2018. College Park will largely remain independent and continue to diligently serve its customer base, while allowing the combined entity to achieve strategic efficiencies. Össur is committed to growing the College Park brand over the coming years both in the United States and international markets. Together, both companies will be well-positioned to enhance their offerings in both lower and upper limb prosthetics. With this acquisition, Össur hopes to support College Park’s focus on the lower active population and further strengthen its established presence in the upper limb arena. Mutual access to technology and products will enable a more comprehensive product and service offering to customers around the

Norsk Hydro: PÅMINNELSE: Invitasjon - Presentasjon av Hydros resultat for andre kvartal 201919.7.2019 14:43:00 CESTPressemelding

Hydros resultat for andre kvartal 2019 blir offentliggjort tirsdag 23. juli 2019 kl. 07.00. Kvartalsrapporten og presentasjonsmaterialet blir samtidig gjort tilgjengelig på www.hydro.com. Presentasjon i Oslo Det blir holdt en kombinert analytikerpresentasjon og pressekonferanse ved Hydros hovedkontor i Drammensveien 260, Oslo, samme dag, kl. 08.30. Resultatet blir presentert av konsernsjef Hilde Merete Aasheim og konserndirektør for Økonomi og finans Eivind Kallevik. Hele presentasjonen kan sees direkte på web-TV. For påmelding, vennligst send mail til ir@hydro.com. I tillegg til web-TV, hvor det vil være mulig å stille spørsmål skriftlig, vil det også være mulig å ringe inn (ikke mulig å stille spørsmål over telefon). Du melder deg på denne telefonkonferansen ved å ringe: Norge +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sverige +46 (0)8 5033 6574 Brasil +55 11 3181 5427 Tyskland +49 (0)89 20303 5709 Kode: 3104804 Q&A / Telefonkonferanse Det blir holdt en telefonkonferans

Norsk Hydro: REMINDER: Invitation - Hydro’s second quarter results 201919.7.2019 14:43:00 CESTPress release

Hydro's second quarter results 2019 will be released at 07:00 CEST (01:00 AM EDT, 06:00 UK time), on Tuesday July 23, 2019. The quarterly report and presentation slides will be available on www.hydro.com at the same time. Presentation in Oslo Hydro will host a combined analyst and press conference, in English, at its corporate headquarters at Drammensveien 260, Oslo, at 08:30 CEST the same day. The presentation will be held by President and CEO Hilde Merete Aasheim and CFO Eivind Kallevik and can also be seen on web TV. To attend the presentation in Oslo, please register by sending a mail to ir@hydro.com. In addition to the webcast, where it will be possible to ask questions in writing, it will also be possible to dial in (not possible to ask questions over the phone). Dial-in numbers for this conference call are: Norway +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sweden +46 (0)8 5033 6574 Brazil +55 11 3181 5427 Germany +49 (0)89 20303 5709 Confirmation Code: 3104804 Q&A

Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma19.7.2019 14:00:00 CESTPressemelding

STOCKHOLM – July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has made a EUR 5 million investment in Forendo Pharma. Claus Andersson, General Partner from Sunstone, joins Forendo Pharma’s Board of Directors. With the investment, Sunstone joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures and Vesalius Biocapital Partners. The new financing will enable Forendo Pharma to progress its lead endometriosis program, FOR-6219, an HSD17B1 enzyme inhibitor, into the next phase of clinical studies after the successful completion of its Phase 1a study earlier this year. Endometriosis is a chronic condition that affects many women of reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments for endometriosis have